Arcturus Therapeutics partnered with Singapore's Duke–NUS Medical School to develop a COVID-19 vaccine.[3] The company also partnered with Catalent, a contract development and manufacturing organization, to manufacture multiple batches of Arcturus' COVID-19 mRNA vaccine candidate.[4]
Clinical trialsEdit
LUNAR-COV19 clinical trials in humans began in July 2020.[5] On 4 January 2021, Arcturus Therapeutics started Phase-2 clinical trials.[6]
^"Arcturus Therapeutics Announces First Quarter 2021 Company Overview and Financial Results and Provides New Clinical Data". Businesswire. 10 May 2021. Retrieved 9 September 2021.
^"Arcturus Therapeutics Announces that it has Initiated Dosing of its COVID-19 STARR™ mRNA Vaccine Candidate, LUNAR-COV19 (ARCT-021) in a Phase 1/2 study". Globe Newswire. 11 August 2020.
^Teo J (15 April 2020). "Coronavirus: Clinical trials for Singapore's vaccine project could start in August". The Straits Times. Retrieved 27 April 2020.
^Stanton D (6 May 2020). "With Arcturus, Catalent bags another COVID project". Bioprocess Insider. Retrieved 8 May 2020.
^Clinical trial number NCT04480957 for "Phase 1/2 Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects" at ClinicalTrials.gov
^"Arcturus Therapeutics Receives FDA Allowance to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate in the". Bloomberg. 4 January 2021. Retrieved 17 January 2021.
^Anwar N (26 November 2020). "Singapore's co-developed vaccine candidate is in 'good shape' for delivery in 2021". CNBC. Retrieved 18 March 2021.
^Cheok M, Mookerjee I (5 August 2020). "Singapore Will Get First Claim to Any Successful Arcturus Vaccine". Bloomberg. Retrieved 18 March 2021.
arct, this, article, about, american, vaccine, other, uses, arcturus, covid, vaccine, also, known, lunar, cov19, covid, vaccine, candidate, developed, arcturus, therapeutics, vaccine, descriptiontargetsars, 2vaccine, typemrnaclinical, dataother, nameslunar, co. This article is about the American vaccine For other uses see Arcturus COVID 19 vaccine ARCT 021 also known as LUNAR COV19 is a COVID 19 vaccine candidate developed by Arcturus Therapeutics ARCT 021Vaccine descriptionTargetSARS CoV 2Vaccine typemRNAClinical dataOther namesLUNAR COV19Routes ofadministrationIntramuscular Contents 1 Medical uses 2 Pharmacology 3 History 3 1 Clinical trials 4 Economics 5 References 6 External linksMedical uses EditIt requires the intramuscular injection with a single dose 1 Pharmacology EditARCT 021 is an mRNA vaccine 2 History EditArcturus Therapeutics partnered with Singapore s Duke NUS Medical School to develop a COVID 19 vaccine 3 The company also partnered with Catalent a contract development and manufacturing organization to manufacture multiple batches of Arcturus COVID 19 mRNA vaccine candidate 4 Clinical trials Edit LUNAR COV19 clinical trials in humans began in July 2020 5 On 4 January 2021 Arcturus Therapeutics started Phase 2 clinical trials 6 Economics EditArcturus has entered into development and supply agreements with the Economic Development Board of Singapore and supply agreements with the Israel Ministry of Health for LUNAR COV19 7 8 References Edit Arcturus Therapeutics Announces First Quarter 2021 Company Overview and Financial Results and Provides New Clinical Data Businesswire 10 May 2021 Retrieved 9 September 2021 Arcturus Therapeutics Announces that it has Initiated Dosing of its COVID 19 STARR mRNA Vaccine Candidate LUNAR COV19 ARCT 021 in a Phase 1 2 study Globe Newswire 11 August 2020 Teo J 15 April 2020 Coronavirus Clinical trials for Singapore s vaccine project could start in August The Straits Times Retrieved 27 April 2020 Stanton D 6 May 2020 With Arcturus Catalent bags another COVID project Bioprocess Insider Retrieved 8 May 2020 Clinical trial number NCT04480957 for Phase 1 2 Ascending Dose Study of Investigational SARS CoV 2 Vaccine ARCT 021 in Healthy Adult Subjects at ClinicalTrials gov Arcturus Therapeutics Receives FDA Allowance to Proceed with Phase 2 Study of ARCT 021 LUNAR COV19 Vaccine Candidate in the Bloomberg 4 January 2021 Retrieved 17 January 2021 Anwar N 26 November 2020 Singapore s co developed vaccine candidate is in good shape for delivery in 2021 CNBC Retrieved 18 March 2021 Cheok M Mookerjee I 5 August 2020 Singapore Will Get First Claim to Any Successful Arcturus Vaccine Bloomberg Retrieved 18 March 2021 External links Edit nbsp Scholia has a profile for Lunar COV19 Q98713328 Portals nbsp Medicine nbsp Viruses nbsp COVID 19 nbsp This article about COVID 19 vaccines is a stub You can help Wikipedia by expanding it vte nbsp This article about vaccines or vaccination is a stub You can help Wikipedia by expanding it vte Retrieved from https en wikipedia org w index php title ARCT 021 amp oldid 1172031376, wikipedia, wiki, book, books, library,
